Older Drivers and THC: A Meta-Analysis Found Null Associations With Important Uncertainty

A 2023 meta-analysis did not find statistically significant associations between THC exposure and either collision involvement or collision culpability among drivers aged 50 and older. Its confidence intervals and study designs prevent interpreting that result as proof of no risk.

Two outcomes were analyzed separately

The review included seven cross-sectional studies: four examined collisions and three examined culpability. Being involved in a collision and being assessed as responsible are different outcomes. A combined statement about cannabis-related crashes should preserve that distinction.

The estimates retained uncertainty

The pooled collision odds ratio was 1.15, with a 95% confidence interval of 0.40–3.31. The culpability estimate was 1.24, with an interval of 0.95–1.61. Both intervals included the null value. The collision estimate was especially imprecise and heterogeneous; lack of statistical significance does not demonstrate equivalence.

Exposure classification is not a functional test

The comparison concerned THC exposure or positivity as defined by the underlying studies. It was not a controlled determination of each driver's impairment at a specified dose. Cross-sectional evidence also leaves important questions about timing, co-exposures and selection of the studied drivers.

Interpreting the evidence

The appropriate conclusion is a non-significant pooled association in this older-driver evidence base, with uncertainty preserved. It does not establish safe cannabis-impaired driving, exclude a meaningful association or resolve whether an individual driver was impaired.

Related reading: interpreting cannabis tolerance claims.

Research reference

Arun Chinna-Meyyappan; Hui Jue Wang; Kritleen K. Bawa; Edward Ellazar; Emilie Norris-Roozmon; Gary Naglie; Nathan Herrmann; Judith L. Charlton; Sjaan Koppel; Saulo Castel; Krista L. Lanctôt; Mark J. Rapoport (2023). Risk of Motor Vehicle Collisions and Culpability among Older Drivers Using Cannabis: A Meta-Analysis. Brain Sciences. doi:10.3390/brainsci13030421.

This analysis draws on the supplied review’s abstract and introductory material.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

A 2017 drug-discovery report described APD371, a selective CB2 agonist, maintaining its effect during a five-day rat osteoarthritis-pain protocol. That short preclinical finding is different from established long-term clinical efficacy. The report concerned selection of a development candidate The authors considered receptor efficacy, pharmacokinetics and pharmaceutical properties alongside an oral…

Spread the love

Read Article: APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

A 2021 rat study found sustained pain-response effects with JWH133 while another CB2 agonist lost efficacy after two days under its repeated-treatment protocol. Shared receptor targeting did not establish equal durability. The compounds were compared in a defined model The experiment used chemically induced osteoarthritis and measured pressure responses and…

Spread the love

Read Article: Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

A 2021 review argued that acute neurocognitive responses to cannabis vary with biological, pharmacological and exposure-related factors. A product label or use-frequency category alone cannot capture all the determinants discussed. The review considered interacting sources of variation It discussed brain-network activity, formulation, use frequency and differences between therapeutic and recreational…

Spread the love

Read Article: An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us